LH

Laboratory
D

LH

Arincen56/100B
366.71
USD
3.41
(0.94%)
Post Trading·366.57USD-0.14(-0.04%)
Fair value489.00Plus-25%367Price 366.71611
Q4 FY2026 · Earnings report
EPS estimate 4.50Revenue estimate 3.75B
OverviewFinancialsForecastEarningsDividendsCompany

Laboratory revenue 1988–2026

Laboratory's revenue in Q3 FY2026, the three months to 30 September 2026, was 3.81B USD, up 6.9% on the same quarter a year before. Laboratory's revenue over the last twelve months was 14.59B USD, up 6.0% on the twelve months before. In fiscal year 2025 it was 13.95B USD, up 7.2% on the year before.

Last updated 6 Nov 2026 · Next report 16 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202614.59B+6.02%4.08B1.00B
FY202531 Dec 202513.95B+7.25%3.73B876.50M
FY202431 Dec 202413.01B+6.97%3.62B746.00M
FY202331 Dec 202312.16B+2.51%3.36B418.00M
FY202231 Dec 202211.86B-9.68%3.71B1.28B
FY202131 Dec 202113.14B-6.03%4.99B2.38B
FY202031 Dec 202013.98B+20.98%4.95B1.56B
FY201931 Dec 201911.55B+1.95%3.25B823.80M
FY201831 Dec 201811.33B+8.54%3.18B883.70M
FY201731 Dec 201710.44B+8.29%3.46B1.27B
FY201631 Dec 20169.64B+11.08%3.18B732.10M
FY201531 Dec 20158.68B+44.39%2.90B436.90M
FY201431 Dec 20146.01B+3.50%2.20B511.20M
FY201331 Dec 20135.81B+2.41%2.22B573.80M
FY201231 Dec 20125.67B+2.33%2.25B583.10M
FY201131 Dec 20115.54B+10.76%2.27B519.70M
FY201031 Dec 20105.00B+6.59%2.10B558.20M
FY200931 Dec 20094.69B+4.21%1.97B543.30M
FY200831 Dec 20084.51B+10.74%1.87B464.50M
FY200731 Dec 20074.07B+13.30%1.69B476.80M
FY200631 Dec 20063.59B+7.91%1.53B431.60M
FY200531 Dec 20053.33B+7.87%1.39B386.20M
FY200431 Dec 20043.08B+4.95%1.29B363.00M
FY200331 Dec 20032.94B+17.21%1.22B321.00M
FY200231 Dec 20022.51B+14.00%1.06B254.60M
FY200131 Dec 20012.20B+14.61%925.60M179.50M
FY200031 Dec 20001.92B+12.99%822.70M112.10M
FY199931 Dec 19991.70B+5.34%682.40M65.40M
FY199831 Dec 19981.61B+6.16%616.80M68.80M
FY199731 Dec 19971.52B-5.52%494.70M-106.90M
FY199631 Dec 19961.61B+12.27%478.70M-153.50M
FY199531 Dec 19951.43B+64.13%453.10M-12.30M
FY199431 Dec 1994872.50M+14.73%303.60M30.10M
FY199331 Dec 1993760.50M+5.42%339.10M112.70M
FY199231 Dec 1992721.40M+19.46%344.90M40.60M
FY199131 Dec 1991603.90M+20.32%293.40M103.90M
FY199031 Dec 1990501.90M+24.73%241.00M82.60M
FY198931 Dec 1989402.40M+28.19%191.10M64.70M
FY198831 Dec 1988313.90M—313.90M49.10M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Laboratory revenue growth by segment

Q3 FY2026 against Q3 FY2025

LabCorp Diagnostics2.95B
+6.5%
Biopharma Laboratory Services866.70M
—

Laboratory revenue by segment over time

LabCorp Diagnostics Clinical diagnostics laboratory Covance Drug Development
Fiscal yearLabCorp DiagnosticsClinical diagnostics laboratoryCovance Drug Development
FY202510.88B +7.2%— —
FY202410.14B +7.7%— —
FY20239.42B +2.3%— 2.77B -51.4%
FY20229.20B -11.2%— 5.71B -2.3%
FY202110.36B — 5.85B
FY20196.66B -0.0%— 2.34B +6.9%
FY20186.66B -53.5%— 2.19B -64.0%
FY201714.34B +117.5%— 6.07B +113.6%
FY20166.59B +6.4%6.59B +6.4%2.84B
FY20156.20B 6.20B +9.1%—

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Laboratory's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.